JPS5188940A - - Google Patents

Info

Publication number
JPS5188940A
JPS5188940A JP50153194A JP15319475A JPS5188940A JP S5188940 A JPS5188940 A JP S5188940A JP 50153194 A JP50153194 A JP 50153194A JP 15319475 A JP15319475 A JP 15319475A JP S5188940 A JPS5188940 A JP S5188940A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP50153194A
Other languages
Japanese (ja)
Other versions
JPS5324064B2 (enExample
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=5934284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5188940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of JPS5188940A publication Critical patent/JPS5188940A/ja
Publication of JPS5324064B2 publication Critical patent/JPS5324064B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP15319475A 1974-12-21 1975-12-22 Expired JPS5324064B2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2460891A DE2460891C2 (de) 1974-12-21 1974-12-21 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
JPS5188940A true JPS5188940A (enExample) 1976-08-04
JPS5324064B2 JPS5324064B2 (enExample) 1978-07-18

Family

ID=5934284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15319475A Expired JPS5324064B2 (enExample) 1974-12-21 1975-12-22

Country Status (16)

Country Link
US (1) US4024175A (enExample)
JP (1) JPS5324064B2 (enExample)
AT (1) AT340892B (enExample)
BE (1) BE836835A (enExample)
CA (1) CA1052811A (enExample)
CH (3) CH612666A5 (enExample)
DE (1) DE2460891C2 (enExample)
DK (1) DK147706C (enExample)
ES (1) ES443723A1 (enExample)
FI (1) FI62282C (enExample)
FR (1) FR2294697A1 (enExample)
GB (1) GB1465229A (enExample)
IE (1) IE42382B1 (enExample)
LU (1) LU74058A1 (enExample)
NL (1) NL181006C (enExample)
SE (1) SE423385B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508362A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
JP2007510695A (ja) * 2003-11-11 2007-04-26 ザンボン　グループ　エス．ピー．エー． ガバペンチンの調製方法
KR100926921B1 (ko) * 2001-06-11 2009-11-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
JP2009542617A (ja) * 2006-06-30 2009-12-03 ザック システム エス．ピー．エー． ガバペンチンの調製プロセス
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
WO2012018095A1 (ja) * 2010-08-06 2012-02-09 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体またはその塩の製造方法
WO2021079887A1 (ja) 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
JPS5776189U (enExample) * 1980-10-28 1982-05-11
JPS6152583U (enExample) * 1984-09-11 1986-04-09
JPS61139881U (enExample) * 1985-02-21 1986-08-29
US4876279A (en) * 1986-05-05 1989-10-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
YU162789A (en) * 1988-09-01 1990-12-31 Lonza Ag 2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
MY106864A (en) * 1989-08-25 1995-08-30 Warner Lambert Co Improved process for cyclic amino acid anticonvulsant compounds.
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
GB8925933D0 (en) * 1989-11-16 1990-01-04 Pfizer Ltd Glutaric acid derivatives and preparation thereof
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5260467A (en) * 1989-11-16 1993-11-09 Pfizer Inc. Glutaric acid derivatives and preparation thereof
FI905584A7 (fi) * 1989-11-16 1991-05-17 Lonza Ag Menetelmä 1-(aminometyyli)sykloheksaanietikkahapon valmistamiseksi
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5157138A (en) * 1989-11-16 1992-10-20 Pfizer, Inc. Glutaric acid derivatives and preparation thereof
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CZ296052B6 (cs) * 1996-02-07 2005-12-14 Warner-Lambert Company Cyklická aminokyselina a farmaceutický prostředek na její bázi
TR199801807T2 (xx) * 1996-03-14 1998-12-21 Warner-Lambert Company Farmas�tik maddeler olarak yeni ikame edilmi� siklik amino asitler.
AU731279B2 (en) * 1996-03-14 2001-03-29 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
DE69722426T3 (de) 1996-07-24 2015-05-07 Warner-Lambert Company LLC (n.Ges. des Staates Delaware) Isobutylgaba und dessen derivate zur schmerzbehandlung
WO1998017627A1 (en) * 1996-10-23 1998-04-30 Warner-Lambert Company Substituted gamma aminobutyric acids as pharmaceutical agents
US6255526B1 (en) 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
AU9019198A (en) 1997-08-19 1999-03-08 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
CA2296336C (en) * 1997-09-08 2004-04-20 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
IL134732A (en) * 1997-10-27 2004-03-28 Warner Lambert Co Acid (S4, S3) (-1 aminomethyl-3,4-dimethyl-cyclopentyl) acetic acid
US6984659B2 (en) * 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
CN1210268C (zh) 1997-12-16 2005-07-13 沃尼尔·朗伯公司 ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
BR9814287A (pt) 1997-12-16 2000-10-03 Warner Lambert Co "4(3)-aminometil-(tio)piran 4(3) substituìdo ou derivados da piperidina (= análogos da gabapentina), sua preparação e seu uso no tratamento de desordens neurológicas"
WO1999037296A1 (en) * 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
DK1077692T3 (da) 1998-05-15 2004-12-06 Warner Lambert Co Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
WO1999059572A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
ES2137137B1 (es) * 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP1082306A1 (en) 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
ITMI981535A1 (it) * 1998-07-03 2000-01-03 Zambon Spa Processo per la preparazione di gabapentina
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
US6710190B1 (en) * 1999-05-28 2004-03-23 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
CA2371089A1 (en) * 1999-05-28 2000-12-07 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
EP1294364A4 (en) * 2000-06-16 2004-06-16 Teva Pharma STABLE GABAPENTINE WITH A PH WITHIN A CONTROLLED AREA
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
DK1289364T3 (da) 2000-06-16 2004-04-13 Teva Pharma Stabil gapapentin som indeholder mere end 20 ppm chlorioner
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
GB2364049A (en) * 2000-06-28 2002-01-16 Warner Lambert Co Cyclic ketones and their use in the synthesis of amino acids
AU2002214978B2 (en) * 2000-09-14 2006-08-31 Gruenenthal Gmbh Beta-Thio-amino acids
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
IT1319234B1 (it) * 2000-10-23 2003-09-26 Zambon Spa Processo di preparazione di gabapentina.
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
KR20030048105A (ko) * 2000-11-02 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 가바펜틴 중간체의 개선된 제조 방법
DE60106968T2 (de) * 2000-11-30 2005-11-03 Pfizer Products Inc., Groton Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
EA200300433A1 (ru) * 2000-11-30 2003-10-30 Пфайзер Продактс Инк. Комбинация гамк-агонистов и ингибиторов альдегидредуктазы
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
US20040063994A1 (en) * 2001-03-16 2004-04-01 Paolo Rossi Process for the preparation of cyclic amino acids
ITMI20011132A1 (it) 2001-05-29 2002-11-29 Procos Spa Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
IL144066A0 (en) * 2001-06-28 2002-04-21 Bromine Compounds Ltd Process for the preparation of 1,1-cyclohexane diacetic monoamide
ITMI20011772A1 (it) 2001-08-10 2003-02-10 A M S A Anonima Materie Sint E Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
EP1423168B1 (en) 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
US6800782B2 (en) * 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
KR20040081478A (ko) * 2002-01-31 2004-09-21 워너-램버트 캄파니 엘엘씨 이명을 치료하기 위한 알파 2 델타 리간드
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080588A1 (en) * 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003089403A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
PL375090A1 (en) * 2002-06-27 2005-11-14 Warner-Lambert Company Llc Method of treating attention deficit hyperactivity disorder
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
US7053122B2 (en) * 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US20040092591A1 (en) * 2002-08-15 2004-05-13 Blakemore David Clive Therapeutic use of fused bicyclic or tricyclic amino acids
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7659305B2 (en) * 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
AU2002356424A1 (en) * 2002-11-18 2004-06-15 Nicholas Piramal India Limited Improved process for preparation of gabapentin
CA2506564C (en) * 2002-11-20 2011-03-29 Hikal Ltd. An improved process for the preparation of gabalactam
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
PL377662A1 (pl) * 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pregabalina i jej pochodne w leczeniu fibromialgii i innych zaburzeń pokrewnych
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
WO2004054564A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
EP1572173B1 (en) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2003303040B2 (en) 2002-12-13 2009-04-23 Warner-Lambert Company Llc Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
GB0301143D0 (en) * 2003-01-17 2003-02-19 Amedis Pharm Ltd Compounds and their use
WO2004065361A2 (en) * 2003-01-22 2004-08-05 Warner-Lambert Company Llc Cyclopropyl beta-amino acid derivatives
JP2006519831A (ja) * 2003-03-07 2006-08-31 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー テトラゾール及びオキサジアゾロン置換β−アミノ酸誘導体
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
DE602004017166D1 (de) * 2003-03-25 2008-11-27 Kiel Lab Inc Gabapentintannat in flüssigen und/oder halbfesten dosierformen
US20040254246A1 (en) * 2003-03-31 2004-12-16 Barrett Ronald W. Treating or preventing hot flashes using prodrugs of GABA analogs
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
ITMI20030825A1 (it) * 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione di gabapentin esente da
EP1615875A2 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Limited Process for the preparation of gabapentin form-ii
KR20060011873A (ko) * 2003-05-16 2006-02-03 화이자 프로덕츠 인코포레이티드 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물
CA2528388A1 (en) * 2003-06-19 2004-12-23 Pfizer Products Inc. Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
CA2572324A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2005025562A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
CN1849153A (zh) 2003-09-12 2006-10-18 辉瑞大药厂 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
MXPA06003043A (es) * 2003-09-17 2006-05-31 Xenoport Inc Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba.
NZ546381A (en) * 2003-10-14 2010-01-29 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
EP2172445A1 (en) * 2004-03-17 2010-04-07 Hikal Limited Cis (z) 4-t-butylgabapentin and its synthesis
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
GB0416228D0 (en) * 2004-07-20 2004-08-25 Sandoz Ind Products S A Process for the preparation of gabapentin
GB0419849D0 (en) * 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
DE602005021907D1 (de) * 2004-09-10 2010-07-29 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal-selektive modulatoren
RU2440112C2 (ru) * 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
EA200800889A1 (ru) * 2005-09-23 2008-12-30 Янссен Фармацевтика, Н. В. Гексагидроциклооктилпиразольные каннабиноидные модуляторы
JP2009508953A (ja) * 2005-09-23 2009-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロ−シクロヘプタピラゾール系カンナビノイドモジュレーター
WO2007035945A1 (en) * 2005-09-23 2007-03-29 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
EP1820502A1 (en) 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
RU2008135907A (ru) * 2006-03-06 2010-04-20 Пфайзер Продактс Инк. (Us) Альфа-2-дельта лиганды для невосстановительного сна
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8012957B2 (en) * 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7442834B2 (en) * 2006-06-12 2008-10-28 Zhejiang Chiral Medicine Chemicals Co., Ltd. Process suitable for industrial scale production of gabapentin
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010512314A (ja) * 2006-12-08 2010-04-22 ゼノポート，インコーポレーテッド 疾患を治療するためのｇａｂａアナログのプロドラッグの使用
BRPI0720351A2 (pt) 2006-12-22 2019-05-14 Recordati Ireland Limited terapia de combinação para distúrbios do trato urinário inferior com ligantes a2o e aines.
WO2008111096A2 (en) * 2007-03-15 2008-09-18 Sun Pharma Advanced Research Company Ltd Novel prodrugs
TW200908957A (en) * 2007-06-15 2009-03-01 Xenoport Inc Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090062392A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched gabapentin
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094563A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101810246B1 (ko) 2008-10-08 2017-12-18 엑스진 파마슈티컬 인크. Ｇａｂａ 접합체 및 그의 사용 방법
US9192681B2 (en) 2009-02-24 2015-11-24 Nektar Therapeutics Oligomer-amino acid conjugates
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2368872A1 (en) 2010-03-25 2011-09-28 Serichim S.r.l. Process for the preparation of Gabapentin
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
US8431739B2 (en) 2010-06-14 2013-04-30 Divi's Laboratories, Ltd. Process for the preparation of gabapentin
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
ITMI20131757A1 (it) 2013-10-22 2015-04-23 Zach System Spa Processo di preparazione di gabapentina
KR20160081864A (ko) 2013-11-01 2016-07-08 가부시키가이샤 도우사 고가쿠 겐큐쇼 티올기를 갖는 d-체 또는 l-체 아미노산 유도체의 제조 방법
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
CN105873580B (zh) 2013-12-17 2020-08-25 埃斯蒂维制药有限公司 加巴喷丁类化合物与σ受体配体的组合物
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
MX388586B (es) 2016-12-16 2025-03-20 Idorsia Pharmaceuticals Ltd Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t.
MX384760B (es) 2018-07-04 2025-03-14 Federico Amezcua Amezcua Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
US10399926B1 (en) 2018-08-01 2019-09-03 Divi's Laboratories Ltd. Process for the preparation of gabapentin
CN112839661A (zh) 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
CN115605195A (zh) 2020-03-04 2023-01-13 普利欧制药有限公司（Us） 用于治疗大麻使用病症和缓解大麻素戒断的方法和组合物
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
GB2625579A (en) 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508362A (ja) * 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
KR100926921B1 (ko) * 2001-06-11 2009-11-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
JP2007510695A (ja) * 2003-11-11 2007-04-26 ザンボン　グループ　エス．ピー．エー． ガバペンチンの調製方法
JP2009542617A (ja) * 2006-06-30 2009-12-03 ザック システム エス．ピー．エー． ガバペンチンの調製プロセス
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
US8946267B2 (en) 2010-07-30 2015-02-03 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
US9226924B2 (en) 2010-07-30 2016-01-05 Toray Industries, Inc. Methods of treating or preventing neuropathic pain
WO2012018095A1 (ja) * 2010-08-06 2012-02-09 杏林製薬株式会社 ビシクロ［２．２．２］オクチルアミン誘導体またはその塩の製造方法
WO2021079887A1 (ja) 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤
JPWO2021079887A1 (enExample) * 2019-10-25 2021-04-29

Also Published As

Publication number Publication date
FI62282B (fi) 1982-08-31
FI62282C (fi) 1982-12-10
NL181006B (nl) 1987-01-02
DE2460891A1 (de) 1976-07-01
FI753613A7 (enExample) 1976-06-22
IE42382B1 (en) 1980-07-30
JPS5324064B2 (enExample) 1978-07-18
DK147706B (da) 1984-11-19
FR2294697B1 (enExample) 1978-07-28
LU74058A1 (enExample) 1976-07-20
AT340892B (de) 1978-01-10
CA1052811A (en) 1979-04-17
SE423385B (sv) 1982-05-03
IE42382L (en) 1976-06-21
BE836835A (fr) 1976-06-18
DK147706C (da) 1985-05-13
NL7514900A (nl) 1976-06-23
CH612666A5 (enExample) 1979-08-15
ATA975075A (de) 1977-05-15
DK581475A (da) 1976-01-22
GB1465229A (en) 1977-02-23
ES443723A1 (es) 1977-04-16
DE2460891C2 (de) 1982-09-23
CH612664A5 (enExample) 1979-08-15
CH612665A5 (enExample) 1979-08-15
US4024175A (en) 1977-05-17
SE7514442L (sv) 1976-06-22
FR2294697A1 (fr) 1976-07-16
AU8774175A (en) 1977-06-23
NL181006C (nl) 1987-06-01

Similar Documents

Publication Publication Date Title
FR2294697B1 (enExample)
FR2230804B3 (enExample)
DK136883C (enExample)
AU479230B2 (enExample)
AR198563A1 (enExample)
AU1893276A (enExample)
CS164324B1 (enExample)
AR198999Q (enExample)
AU480660A (enExample)
AU490706A (enExample)
AU480049A (enExample)
DD117038A5 (enExample)
AU479769A (enExample)
AU479768A (enExample)
AU479725A (enExample)
AU479448A (enExample)
DD116999A1 (enExample)
DD120463A5 (enExample)
AU480308A (enExample)
DD111629A1 (enExample)
AU480465A (enExample)
AU482364A (enExample)
DD109933A1 (enExample)
DD119250A5 (enExample)
CH610549A5 (enExample)